GlassScriptPhysician profile
Glen L Nadel
NPI 1548231400
$11,989.77
in general payments reported to CMS, 2019-2025
32 companies · $2,546 in 2025
The $2,546 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,624 · 2020: $1,330 · 2021: $1,689 · 2022: $1,330 · 2023: $1,582 · 2024: $1,888 · 2025: $2,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,869 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,868.73 |
| Education | $147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,637.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,597.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,579.51 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $989.52 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $713.30 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $659.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $601.70 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $504.14 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $383.87 | 2019-2024 | |
| Genentech USA, INC. | $380.32 | 2019-2025 | Xolair |
| Csl Behring | $377.50 | 2019-2025 | Hizentra, Haegarda |
| Abbvie INC. | $374.38 | 2021-2025 | |
| Covis Pharma Gmbh | $330.28 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $311.97 | 2019-2021 | |
| Amgen INC. | $277.92 | 2021-2025 | Tezspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.48 | 2019-2023 | Spiriva Respimat |
| Kaleo, INC. | $161.00 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $116.83 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $114.91 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $104.12 | 2022-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Organon LLC | $86.93 | 2025 | Vtama |
| Alk-Abello, INC | $73.71 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Cycle Pharmaceuticals INC | $58.04 | 2024-2025 | Sajazir |
| Aimmune Therapeutics, INC. | $46.56 | 2020-2022 | |
| Galderma Laboratories, L.P. | $43.18 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $37.49 | 2025 | Neffy |
| Verona Pharma, INC. | $33.00 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $30.42 | 2022 | |
| Blueprint Medicines Corporation | $25.91 | 2023 | Ayvakit |
| Dermavant Sciences, INC. | $21.04 | 2024 | Vtama |
| Viatris Specialty LLC | $14.36 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Nadel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.